Abstract:Introduction Autoimmune response to self-antigens results in autoantibodies (AAbs), wherein AAbs against extra cellular loop 2 (ECL2) of β1AR is known to underlie dilated cardiomyopathy (DCM). Contrarily, recent studies show that patients with β1AR AAbs belonging to the IgG3 subclass have beneficial outcomes. However, the signaling mechanisms that underlie the beneficial outcomes are not well understood. Hypothesis IgG3(+) β1AR AAbs facilitates uniquely biased β1AR signaling in response to β-blockers. Methods Since IgG3(+) β1AR AAbs are associated with favorable patient outcomes, in silico studies were conducted to evaluate the interaction between the IgG3(+) antibody and the known structure of β1AR. In silico epitope prediction suggested that the extracellular loop 1 (ECL1) could be a potential epitope, wherein binding by IgG3(+) AAbs at ECL1 could facilitate unique biased signaling in response to β-blockers. Peptides representing human β1AR ECL 1 was synthesized and antibodies targeting the human β1AR ECL 1 was generated by immunizing the mice. HEK 293 cells expressing human β1AR were pre-treated with serum containing antibodies against ECL 1 of β1AR followed by either β1AR selective agonist dobutamine (DOB) or β-blocker metoprolol stimulation. Downstream β1AR signaling was measured by cAMP generation. To test for specificity of ECL1 in the modulating β1AR responses, the cells were incubated with ECL 1 peptides along with antibodies against ECL1 of human β1AR as competitors and cAMP generation assessed following metoprolol. Results Treatment of human β1AR expressing HEK 293 cells with serum from mouse immunized with ECL1 of human β1AR showed no baseline changes in the cAMP generation. However, pretreatment of these cells with ECL1 antibodies followed by stimulation with DOB surprisingly showed marked reduction in cAMP generation in contrast to adjuvant controls which showed significant increase in cAMP. While, treatment of these ECL1 antibody pretreated cells with metoprolol unexpectedly resulted in cAMP generation which is blocked in the adjuvant controls. This shows that antibodies against the ECL1 of human β1AR binds to the β1AR and is able to allosterically modulate downstream signaling mediated by agonist (DOB) or β-blocker (metoprolol) as at baseline it does not alter β1AR function. To validate that antibodies against the ECL1 of human β1AR allosterically modulates metoprolol signaling, the cells were also pre-treated with competing doses of ECL1 peptide followed by metoprolol treatment. Consistent with our hypothesis, incubation with ECL1 peptide remarkably blocked cAMP generation in response to metoprolol. This shows that antibody binding to the ECL1 of human β1AR mediates this unique signaling in response to metoprolol wherein, a traditionally cAMP blocking β-blocker metoprolol now mediates cAMP generation. Conclusions These observations suggest that the allosteric binding of β1AR ECL1 by the antibodies mediates unexpected downstream signal that could underlie the benefits observed in the patients harboring IgG3(+) AAbs. Mechanisms underlying this unique allosteric modulation will be discussed in our presentation.

Effects of autoantibodies against β1-adrenoceptors induced by hepatitis viruses on L-type Ca2+ currents and intracellular Ca2+ concentration

Pro-arrhythmic action of autoantibodies against the second extracellular loop of β1-adrenoceptor and its underlying molecular mechanisms

[Effect of Adriamycin on Sarcoplasmic Reticulum Ca2+ -Atpase Activity in Cardiomyocyte of Rabbits]

BISOPROLOL INHIBITS SODIUM CURRENT IN VENTRICULAR MYOCYTES OF RATS WITH DIASTOLIC HEART FAILURE

Effects of Autoantibodies Against AT1 Receptor from Patients with Refractory Hypertension on Intracellular Ca2+ Mobilization of Rat Vascular Smooth Muscle Cells

[The Proarrhythmic Effects of Autoantibody Against Beta1 Adrenergic Receptor].

Impact on the Cardiac Function and Autoantibodies Against the Cardiac Β1-Adrenergic and M2-muscarinic Receptors As Treated with Bisoprolol at Target Dosage in Patients with Chronic Heart Failure

Effects of adenosine on action potential and L-type calcium channel current in Guinea-pig ventricular myocytes under normal and imitated ischemia-reperfusion conditions

Effects of Valsartan on Ion Channel Currents of Guinea Pig Ventricular Myocytes

Effects of Bromibenzyltetrahydraberberine on Ion Channels in Guinea Pig Ventricular Myocytes

Effects of Autoantibodies Against the Angiotensin II Receptor on Rat Ventricular Myocardial Ionic Currents

Effects of Hyperthyroidism on the Electrophysiological Characteristics Between Atrium and Gap Junction Between Atrium and Pulmonary Vein

Effect of Β-Blockers on Cardiac Function and Calcium Handling Protein in Postinfarction Heart Failure Rats

Study of Mechanism of Adenosine Antagonized Isoproterenol on Action Potentials andlnward Rectifier Potassium Channels in Guinea Pig Papillary Muscles and Ventricular Myocytes

Effects of angiotensin-1 receptor autoantibodies on the myocardial structure and function of rats

An Electrophysiological Study on the Anti-Ventricular Arrhythmic Effect of Adenosine in the Guinea Pig

Effects of Valsartan on the Action Potential of Guinea Pig Ventricular Myocytes

[Effects of Chronic Amiodarone Therapy on L-type Calcium Current Recovery and Action Potential Duration of Rabbit Ventricular Myocytes].

Effects of adenosine in simulated ischemia and reperfusion on isolated guinea-pig ventricular myocytes

β1-adrenergic Receptor (β1AR) Autoantibodies Endogenously Bias β1AR Signaling

[Autoantibodies Against the Myocardium Beta 1-Adrenergic and M2-muscarinic Receptors in Patients with Heart Failure].